BioSpace News Archive

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company committed to being the leader in responsible pain management, announced its 2021 full-year financial guidance.

iCAD, Inc., a global medical technology leader providing innovative cancer detection and therapy solutions, announced that it will participate in the 10th Annual LifeSci Partners Corporate Access Event, January 6-8 and 11-14, 2021.

Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to participate in a virtual fireside chat at the H.C. Wainwright BioConnect 2021 Virtual Conference taking place January 11-14, 2021. The presentation will be available for on-demand listening beginning January 11, 2021 at 6:00 AM Eastern Time. Interested parties may access the recorded webcast of thi

Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, announced today that it has commenced an underwritten public offering of its common stock. In connection with the offering, Harpoon Therapeutics intends to grant the underwriters in the offering a 30-day option to purchase up to an additional 15 percent of the number of shares sold. Harpoon Therapeutics p

CorWave reported today it has raised $40M from returning investors and three new investors. The company is developing an implantable heart pump (Left Ventricular Assist Device, LVAD) based on a breakthrough technology: the wave membrane pump . These new funds will enable CorWave to finalize development of its initial product, expand a manufacturing infrastructure, complete regulatory testing required to conduct human

Jnana Therapeutics , a biotechnology company targeting the solute carrier (SLC) family of metabolite transporters to treat underserved diseases, today announced the appointment of two experienced scientific and clinical leaders to the company’s boards. Annie C. Chen, MD, MPH, Chief Medical Officer of Nimbus Therape

Vaxcyte, Inc., a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide, today announced the publication of preclinical data for VAX-A1, the Company’s novel Group A Streptococcus (Group A Strep) conjugate vaccine candidate, in the journal Infectious Microbes & Diseases . Group A Strep is

Company to Expand R&D Focus for Pipeline Growth to include Earlier Stage Programs and Validated Technology Platforms Firdapse® 2020 Net Revenues Estimate of approximately $118 Million; about 16% Increase From 2019 Ended 2020 with Estimated $140 Million in Cash and Investments Company Highlights Current Product Development Programs

UroGen Pharma to Present at the Virtual 39 th Annual J.P. Morgan Healthcare Conference

Pamela Holland, Ph.D., Joins as Senior Vice President, Research Remy Durand, Ph.D., Promoted to Chief Business Officer